AstraZeneca Top Drugs by Sales 2024 (Total Revenue)
See AstraZeneca’s 2024 total revenue by key marketed medicine—Tagrisso, Farxiga, Imfinzi, Lynparza, Symbicort and more (USD millions).
Here is a consolidated table of AstraZeneca’s key marketed medicines and their 2024 Total Revenue, using the brand name as “Drug name” and the non‑proprietary name in parentheses as “Bio name.” Amounts are in USD millions for 2024.
| Drug name (brand) | Bio name (non‑proprietary) | 2024 sales, Total Revenue (USD m) |
| --- | --- | --- |
| Tagrisso | osimertinib | 6,580 ["Tagrisso (osimertinib)… $6,580m"](0001104659-25-014750|7) |
| Imfinzi | durvalumab | 4,717 ["Imfinzi (durvalumab)… $4,717m"](0001104659-25-014750|7) |
| Calquence | acalabrutinib | 3,129 ["Calquence (acalabrutinib)… $3,129m"](0001104659-25-014750|7) |
| Lynparza | olaparib | 3,672 ["Lynparza (olaparib)… $3,672m"](0001104659-25-014750|7) |
| Enhertu | trastuzumab deruxtecan | 1,982 ["Enhertu (trastuzumab deruxtecan)… $1,982m"](0001104659-25-014750|7) |
| Zoladex | goserelin acetate | 1,097 ["Zoladex (goserelin acetate implant)… $1,097m"](0001104659-25-014750|7) |
| Imjudo | tremelimumab | 281 ["Imjudo (tremelimumab)… $281m"](0001104659-25-014750|7) |
| Truqap | capivasertib | 430 ["Truqap (capivasertib)… $430m"](0001104659-25-014750|7) |
| Orpathys | savolitinib | 46 ["Orpathys (savolitinib)… $46m"](0001104659-25-014750|7) |
| Farxiga / Forxiga | dapagliflozin | 7,717 ["Farxiga/Forxiga (dapagliflozin)… $7,717m"](0001104659-25-014750|7) |
| Brilinta / Brilique | ticagrelor | 1,333 ["Brilinta/Brilique (ticagrelor)… $1,333m"](0001104659-25-014750|7) |
| Crestor | rosuvastatin calcium | 1,155 ["Crestor (rosuvastatin calcium)… $1,155m"](0001104659-25-014750|7) |
| Seloken / Toprol‑XL | metoprolol succinate | 606 ["Seloken/Toprol-XL (metoprolol succinate)… $606m"](0001104659-25-014750|7) |
| Lokelma | sodium zirconium cyclosilicate | 542 ["Lokelma (sodium zirconium cyclosilicate)… $542m"](0001104659-25-014750|7) |
| Roxadustat | roxadustat | 336 ["Roxadustat… $336m"](0001104659-25-014750|7) |
| Andexxa / Ondexxya | andexanet alfa | 219 ["Andexxa/Ondexxya (andexanet alfa)… $219m"](0001104659-25-014750|7) |
| Wainua / Wainzua | eplontersen | 85 ["Wainua/Wainzua (eplontersen)… $85m"](0001104659-25-014750|7) |
| Symbicort | budesonide + formoterol | 2,879 ["Symbicort (budesonide/ formoterol)… $2,879m"](0001104659-25-014750|7) |
| Fasenra | benralizumab | 1,689 ["Fasenra (benralizumab)… $1,689m"](0001104659-25-014750|7) |
| Pulmicort | budesonide | 682 ["Pulmicort (budesonide)… $682m"](0001104659-25-014750|7) |
| Breztri / Trixeo | budesonide + glycopyrrolate + formoterol | 978 ["Breztri/Trixeo (budesonide/ glycopyrrolate/ formoterol)… $978m"](0001104659-25-014750|7) |
| Tezspire | tezepelumab | 684 ["Tezspire (tezepelumab)… $684m"](0001104659-25-014750|7) |
| Saphnelo | anifrolumab | 474 ["Saphnelo (anifrolumab)… $474m"](0001104659-25-014750|7) |
| Airsupra | albuterol + budesonide | 66 ["Airsupra (albuterol/budesonide)… $66m"](0001104659-25-014750|7) |
| Beyfortus | nirsevimab | 722 ["Beyfortus (nirsevimab)… $722m"](0001104659-25-014750|7) |
| Synagis | palivizumab | 447 ["Synagis (palivizumab)… $447m"](0001104659-25-014750|7) |
| FluMist | live attenuated influenza vaccine | 258 ["FluMist (live attenuated influenza vaccine)… $258m"](0001104659-25-014750|7) |
| COVID‑19 mAbs | tixagevimab + cilgavimab; sipavibart | 31 ["COVID-19 mAbs1 (tixagevimab and cilgavimab, and sipavibart)… $31m"](0001104659-25-014750|7) |
| Ultomiris | ravulizumab (plus Voydeya revenue) | 3,924 ["Ultomiris1 (ravulizumab)… $3,924m"](0001104659-25-014750|7) |
| Soliris | eculizumab | 2,588 ["Soliris2 (eculizumab)… $2,588m"](0001104659-25-014750|7) |
| Strensiq | asfotase alfa | 1,416 ["Strensiq (asfotase alfa)… $1,416m"](0001104659-25-014750|7) |
| Koselugo | selumetinib | 631 ["Koselugo (selumetinib)… $631m"](0001104659-25-014750|7) |
| Kanuma | sebelipase alfa | 209 ["Kanuma (sebelipase alfa)… $209m"](0001104659-25-014750|7) |
All figures are AstraZeneca’s reported **Total Revenue for 2024** by product in its “Key marketed products” tables in the 2024 Annual Report & Form 20‑F Information.